IRVINE, Calif., May 12 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX pre split, NUXP post split) today announced that on May 9th, the Company's 1-for-4 reverse stock split became effective. The Company has been informed by the Over The Counter Bulletin Board's Corporate Actions group that, in connection with the reverse stock split, its trading symbol has changed from NURX to NUXP.
The reverse stock split will reduce the number of issued and outstanding shares of NuRx's common stock from approximately 129.5 million shares (on a fully diluted basis) to approximately 34.3 million shares.
NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX5183, an RAR agonist for the treatment of acute leukemia, and NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceuticals.com.
The above information contains information relating to the Company that
is based on the beliefs of the Company and/or its management as well as
assumptions made by and information currently available to the Company or
its management. The Company, from time to time, may discuss forward-looking
information. Except for the historical information contained in this news
release, all forward-looking statements are predictions by the Company's
management and are subject to various risks and uncertainties that may
cause results to differ from management's current expectations. Such
factors include the fact that the Company is engaged in early stage
research and does not expect to obtain any revenues for several years and
other risks as detailed from time to time in the Company's registration
statement and reports and filings with the Securities and Exchange
Commission. All forward-looking statements, if any, in this news release
represent the Company's judgment as of the date of this news release. The
Company disclaims, however, any intent or obligation to update
|SOURCE NuRx Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved